Literature DB >> 26436767

Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.

Chih-Yung Yang1, Hong-Wen Liu2, Ya-Ching Tsai2, Ju-Yu Tseng2, Shu-Ching Liang2, Chin-Yau Chen3, Wei-Nan Lian2, Ming-Cheng Wei4, Maggie Lu4, Ruey-Hwa Lu5, Chi-Hung Lin1,2,6, Jeng-Kai Jiang6,7.   

Abstract

Our previous studies showed that colorectal tumor has high interleukin-4 receptor α (IL-4Rα) expression, whereas adjacent normal tissue has low or no IL-4Rα expression. We also observed that human atherosclerotic plaque-specific peptide-1 (AP1) can specifically target to IL-4Rα. In this study, we investigated the therapeutic efficacy and systemic toxicity of AP1-conjuagted liposomal doxorubicin. AP1 bound more strongly to and was more efficiently internalized into IL-4Rα-overexpressing CT26 cells than CT26 control cells. Selective cytotoxicity experiment revealed that AP1-conjugated liposomal doxorubicin preferentially killed IL-4Rα-overexpressing CT26 cells. AP1-conjugated liposomal doxorubicin administered intravenously into mice produced significant inhibition of tumor growth and showed decreased cardiotoxicity of doxorubicin. These results indicated that AP1-conjugated liposomal doxorubicin has a potent and selective anticancer potential against IL-4Rα-overexpressing colorectal cancer cells, thus providing a model for targeted anticancer therapy.

Entities:  

Keywords:  AP1; colorectal cancer; interleukin-4 receptor α; targeted drug delivery

Mesh：

Substances：

Year:  2015        PMID： 26436767      PMCID： PMC4846110          DOI： 10.1080/15384047.2015.1095397

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  59 in total

1.  Drug delivery systems: entering the mainstream.

Authors:  Theresa M Allen; Pieter R Cullis
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

Review 2.  Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.

Authors:  K Kawakami; M Kawakami; R K Puri
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

3.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

Review 4.  Developments in liposomal drug delivery systems.

Authors:  N Maurer; D B Fenske; P R Cullis
Journal:  Expert Opin Biol Ther       Date:  2001-11       Impact factor: 4.388

5.  Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells.

Authors:  K Kawakami; P Leland; R K Puri
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

6.  Targeting interleukin-4 receptors for effective pancreatic cancer therapy.

Authors:  Koji Kawakami; Mariko Kawakami; Syed R Husain; Raj K Puri
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

7.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

Authors:  Friedrich Weber; Anthony Asher; Richard Bucholz; Mitchel Berger; Michael Prados; Susan Chang; Jeffrey Bruce; Walter Hall; Nikolai G Rainov; Manfred Westphal; Ronald E Warnick; Robert W Rand; Frank Floeth; Frank Rommel; Henry Pan; Vijay N Hingorani; Raj K Puri
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

8.  Interleukin-4 and interleukin-13 signaling connections maps.

Authors:  Ann E Kelly-Welch; Erica M Hanson; Mark R Boothby; Achsah D Keegan
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

9.  Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.

Authors:  P Leland; J Taguchi; S R Husain; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  2000-03       Impact factor: 6.376

10.  A THEMIS:SHP1 complex promotes T-cell survival.

Authors:  Wolfgang Paster; Annika M Bruger; Kristin Katsch; Claude Grégoire; Romain Roncagalli; Guo Fu; Nicholas R J Gascoigne; Konstantina Nika; Andre Cohnen; Stephan M Feller; Philip C Simister; Kelly C Molder; Shaun-Paul Cordoba; Omer Dushek; Bernard Malissen; Oreste Acuto
Journal:  EMBO J       Date:  2014-12-22       Impact factor: 11.598
View more
  4 in total

1.  Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum.

Authors:  Kyoung Min Kim; Usama Khamis Hussein; See-Hyoung Park; Young Jae Moon; Zhongkai Zhang; Asmaa Gamal Ahmed; Ae-Ri Ahn; Ho Sung Park; Jung Ryul Kim; Kyu Yun Jang
Journal:  Diagn Pathol       Date:  2021-01-09       Impact factor: 2.644

Review 2.  Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.

Authors:  Bhalchandra Mirlekar
Journal:  SAGE Open Med       Date:  2022-01-25

Review 3.  Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.

Authors:  Hailong Tian; Tingting Zhang; Siyuan Qin; Zhao Huang; Li Zhou; Jiayan Shi; Edouard C Nice; Na Xie; Canhua Huang; Zhisen Shen
Journal:  J Hematol Oncol       Date:  2022-09-12       Impact factor: 23.168

4.  Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer.

Authors:  Prakash Gangadaran; Gowri Rangaswamy Gunassekaran; Ramya Lakshmi Rajendran; Ji Min Oh; Sri Murugan Poongkavithai Vadevoo; Ho Won Lee; Chae Moon Hong; Byungheon Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Biomedicines       Date:  2022-08-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.